Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Stopped early · Phase 3
Conditions studied: Gastrointestinal Stromal Tumors
In brief
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Key facts
- Study ID
- NCT00812240
- Run by
- AB Science
- People needed
- 335
- Starts
- 2009-01-01
- Expected to finish
- 2018-07-01
- Last updated by the study team
- 2023-02-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- MD Anderson Cancer Center — Orlando, Florida, United States
- The Emory Clinic — Atlanta, Georgia, United States
- Henry Ford Health System — Detroit, Michigan, United States
- Beth Israel Medical Center — New York, New York, United States
- Ohio State University — Columbus, Ohio, United States
- Cancer Centers of the Carolinas — Greenville, South Carolina, United States
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Centre Hospitalier d'Abbeville — Abbeville, France
- Institut Sainte Catherine — Avignon, France
- Hôpital Jean Minjoz — Besançon, France
- Institut Bergonié — Bordeaux, France
- Hôpital Morvan — Brest, France
- Hôpitalo Henri Mondor — Créteil, France
- Centre Georges François Leclerc — Dijon, France
- Hopital Bocage — Dijon, France
- Centre Hospitalier Victor Jousselin — Dreux, France
- Clinique Pasteur — Évreux, France
- Centre Hospitalier de Gap — Gap, France
- CHD de Vendée — La Roche-sur-Yon, France
- Centre Hsopitalier de La Rochelle — La Rochelle, France
- Centre Hospitalier Robert Boulin — Libourne, France
- Centre Oscar Lambret — Lille, France
- Centre Léon Bérard — Lyon, France
- Institut Paoli Calmette — Marseille, France
- Centre Val d'Aurèle — Montpellier, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.